TCW Group Inc. Sells 16,921 Shares of Merck & Co., Inc. $MRK

Key Points

• TCW Group reduced its Merck position by 2%, selling 16,921 shares in the second quarter and retaining 845,538 shares valued at approximately $108.7 million. Institutional investors collectively own 76.07% of MRK.
• Merck and Moderna reported positive Phase 3 results for their personalized mRNA vaccine combined with Keytruda in high-risk melanoma, potentially strengthening Merck’s oncology pipeline ahead of Keytruda’s expected loss of exclusivity.
• MRK faces mixed market signals: several analysts raised price targets following the trial results, but RBC and Jefferies cited valuation concerns and Keytruda-related risks. The stock opened at $149.25, near its 52-week high, while insiders have sold roughly $30 million in shares over the past three months.

TCW Group Inc. lessened its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 845,538 shares of the company's stock after selling 16,921 shares during the quarter. TCW Group Inc.'s holdings in Merck & Co., Inc. were worth $108,652,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MRK. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $25,000. Abound Financial LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $26,000. High Note Wealth LLC grew its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. Institutional investors own 76.07% of the company's stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their individualized mRNA vaccine, used with Merck’s Keytruda, met the Phase 3 primary endpoint in high-risk melanoma. The combination improved recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, marking the first positive late-stage result for an mRNA cancer vaccine. The result could expand Merck’s oncology pipeline and help address the eventual loss of Keytruda exclusivity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: Morgan Stanley upgraded MRK to overweight and raised its price target to $179 from $116, while UBS lifted its target to $175 and BMO raised its target to $170, reflecting increased confidence in the cancer-vaccine opportunity and Merck’s broader growth prospects. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Neutral Sentiment: Analysts cautioned that the initial results are not a complete regulatory or commercial victory. Full data, regulatory approval expected no earlier than 2027, manufacturing execution and the therapy’s eventual pricing and market adoption remain key uncertainties. Moderna's Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
• Negative Sentiment: RBC downgraded MRK to sector perform and set a $150 target, arguing that the roughly $150 valuation is unusually demanding for a company facing a major Keytruda loss of exclusivity in about two years. Jefferies also moved the stock to hold, creating a valuation overhang despite the trial success. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Broader healthcare weakness and profit-taking after Merck’s sharp rally are adding pressure, while the stock’s elevated valuation leaves less room for disappointment. Sector Update: Healthcare Stocks Fall Thursday Afternoon

Insider Transactions at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 80,315 shares of the company's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard R. Deluca sold 20,784 shares of the firm's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the transaction, the executive vice president directly owned 134,703 shares of the company's stock, valued at $17,569,312.29. The trade was a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

MRK has been the topic of several recent research reports. Bank of America increased their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a research report on Tuesday, June 30th. Weiss Ratings lowered Merck & Co., Inc. from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday, August 11th. BMO Capital Markets raised their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday. Jefferies Financial Group downgraded Merck & Co., Inc. from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Finally, Wall Street Zen lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Monday, July 20th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $142.10.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $149.25 on Friday. The stock's 50-day simple moving average is $127.43 and its 200-day simple moving average is $121.01. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $153.50. The company has a market capitalization of $368.23 billion, a price-to-earnings ratio of 119.40, a PEG ratio of 6.56 and a beta of 0.19. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the company earned $2.13 EPS. The firm's quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source